Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether ThermoDox, a thermally sensitive liposomal
doxorubicin, is effective in the treatment of non-resectable hepatocellular carcinoma when
used in conjunction with radiofrequency ablation (RFA).